Cargando…
Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells
BACKGROUND: The efficacy and safety of multikinase inhibitor anlotinib have been confirmed in the treatment of advanced non-small cell lung cancer (NSCLC). However, the direct functional mechanisms of tumor lethality mediated by anlotinib were not fully elucidated, and the underlying mechanisms rela...
Autores principales: | Liang, Lijun, Hui, Kaiyuan, Hu, Chenxi, Wen, Yixuan, Yang, Shikun, Zhu, Panrong, Wang, Lei, Xia, Youyou, Qiao, Yun, Sun, Wen, Fei, Jiayan, Chen, Ting, Zhao, Fenghua, Yang, Baocheng, Jiang, Xiaodong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373028/ https://www.ncbi.nlm.nih.gov/pubmed/30755242 http://dx.doi.org/10.1186/s13046-019-1093-3 |
Ejemplares similares
-
Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report
por: Liang, Lijun, et al.
Publicado: (2017) -
Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
por: Wang, Zhi‐Ming, et al.
Publicado: (2020) -
The role and significance of VEGFR2(+) regulatory T cells in tumor immunity
por: Zhu, Panrong, et al.
Publicado: (2017) -
NEAT 1 knockdown enhances the sensitivity of human non-small-cell lung cancer cells to anlotinib
por: Gu, Guoqing, et al.
Publicado: (2021) -
Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A
por: Gu, Guoqing, et al.
Publicado: (2021)